Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Editas Medicine (EDIT) plans to submit IND application for LCA10, a vaccine for eye disease,in the middle of 2018

Source Link:: http://seekingalpha.com/pr/16764379-editas-medicine-announces-fourth-quarter-full-year-2016-results-update

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

EDIT

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Initially expected by end of 2017, the target date for filing the IND application for the LCA10 program is being moved to the middle of 2018 to accommodate certain delays in third-party manufacturing of our LCA10 product candidate and to take full advantage of our newly formed alliance with Allergan.

http://seekingalpha....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Nov 30, 2018

Occurred Source:

https://www.genengnews.com/news/editas-wins-fda-approval-for-ind-of-crispr-treatment-for-lca10/

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Lca10, Eye Disease, Ind Filing